Last update 24 May 2024

Brolucizumab-dbll

Overview

Basic Info

Drug Type
Single-chain FV antibody fragment
Synonyms
brolucizumab, Brolucizumab (Genetical Recombination), 布罗鲁珠单抗
+ [9]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Brolucizumab-dbll

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic macular oedema
JP
25 Mar 2020
Dystrophy, Macular
JP
25 Mar 2020
Wet age-related macular degeneration
US
07 Oct 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pachychoroid NeovasculopathyPhase 3-01 Jan 2023
Proliferative retinopathy with diabetes mellitusPhase 3
US
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
US
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
US
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
US
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
CN
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
JP
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
JP
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
JP
19 Nov 2020
Proliferative retinopathy with diabetes mellitusPhase 3
JP
19 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
689
gwmodkbbni(qxssebazwk) = eklevuryde nftzciloth (ubpacfaomk )
Positive
09 May 2024
PRP
gwmodkbbni(qxssebazwk) = xrzysobjlo nftzciloth (ubpacfaomk )
Phase 3
689
brolucizumab 6mg
wfljsfvehc(ydxwzwxtge) = The 1-year result from the CONDOR study affirms the efficacy of brolucizumab 6mg in the treatment of PDR and the expected safety profile. ecwpiyvrkc (kvepflydad )
Superior
09 May 2024
panretinal photocoagulation
Phase 3
248
jhssmurprx(jdecvhiies) = vaujxgmffn dmvddeqgjz (qrrwsbldjj, furteeykdy - rxsxtobcdp)
-
04 Apr 2024
Not Applicable
31
Brolucizumab
dvtzzqzouy(ylhatfytlk) = wqrgbntkru pguglmpkhl (qdfmwlspuw )
-
23 Apr 2023
Brolucizumab
dvtzzqzouy(ylhatfytlk) = osceduevni pguglmpkhl (qdfmwlspuw )
Not Applicable
82
Intravitreal brolucizumab (IVBr)
bngtncazya(fvxrjdukvt) = lutfhyleum nwkjrtgudh (rsdjncisxc, 0.36)
Positive
23 Apr 2023
Intravitreal faricimab (IVF)
bngtncazya(fvxrjdukvt) = lgnwxmddxe nwkjrtgudh (rsdjncisxc, 0.38)
Not Applicable
Wet age-related macular degeneration
retinal fluid | structural components of the retina and choroid | prechoroidal cleft ...
81
cvbhwrglqq(laqyaspoty) = worsened early after switching zofjmhrksc (gaulmcsjwv )
-
23 Apr 2023
Not Applicable
482
brolucizumab
qqorpwrebn(ovbujkgcba) = IOI-related ocular AEs occurred in 22/482 (4.6%) eyes and the most common single AE types were posterior uveitis (5 eyes, 1.0%), anterior uveitis (4 eyes, 0.8%), and panuveitis (4 eyes, 0.8%). Another 4 eyes (0.8%) had retinal vasculitis (RV) and of these, 1 had concomitant anterior uveitis and 2 (0.4%) had concomitant retinal vascular occlusion (RO, 1 also with panuveitis). Two of the eyes with IOI+RV (one of which also had RO) had vision loss of ≥15 letters representing a 0.4% (2/482) overall risk of developing IOI of any form and experiencing at least moderate vision loss. The majority of eyes (14/22 [64%]) developed the AE within 3 months of the first brolucizumab injection, 4/22 (18%) within 3-6 months and the remaining 4/22 (18%) within 6-18 months. IOI-related AEs mostly occurred within the first few brolucizumab injections (median 3 injections; range, 1-8). Eyes with IOI-related AEs lost a median (interquartile range) of -6.8 (-19.9-0.0) ETDRS letters at the time of the AE compared with their last visual acuity (VA) measurement prior to the AE. Taking the best VA at either 3 or 6 months after AE resolution/stability, VA was preserved (i.e., decreased by <5 letters compared with prior to the AE) in 18 (82%) of the 22 affected eyes. npnazvuwso (qkpyrvhpll )
-
23 Apr 2023
brolucizumab
Not Applicable
-
kmnvvuzpis(hwjjmyhwuk) = kkielobtek nqwqnetsjk (foogaejjwn )
-
29 Sep 2022
Phase 3
-
byxelnpcla(ftcuazanau): difference = -0.6 (95% CI, -2.1 to 0.9), P-Value = <0.001
Negative
07 May 2022
Aflibercept
Phase 3
-
bfrbytvyxn(wwcpqgktkk) = gojvlengdv tnafkxyamo (pxwmwareet )
Positive
01 May 2022
bfrbytvyxn(wwcpqgktkk) = hlmegoklhb tnafkxyamo (pxwmwareet )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free